Second medical use is currently a hot topic in pharmaceutical patents. In the dispute over the breast cancer drug containing the active ingredient fulvestrant, the generics manufacturers have landed a further victory. Düsseldorf Higher Regional Court yesterday dismissed AstraZeneca’s appeal and an application for a preliminary injunction after only two hours of negotiations (case IDs: I-2 U 27/18, I-2 U 28/18, I-2 U 29/18).
Representatives:
For AstraZeneca
Hoffmann Eitle (Munich): Dirk Schüßler-Langeheine, Michael Pfeifer, Thorsten Bausch, Ulrike Ciesla (both patent attorneys)
Novacos (Düsseldorf): Christian Stallberg
In-house (Macclesfield): Lucy Padget (senior patent director)
For Hexal
Arnold Ruess (Düsseldorf): Cordula Schumacher, Marina Wehler, Lisa Schneider
df-mp Dörries Frank-Molnia & Pohlman (Munich): Elisabeth Greiner, Holger Schimmel (both patent attorneys)
Taylor Wessing (Munich): Manja Epping
In-house (Holzkirchen): Patricia Paias, Waltraud Fauss-Berghus
For Ratiopharm
Bird & Bird (Düsseldorf): Oliver Jüngst, Anna Wolters-Höhne, Annika Schneider,
Lederer & Keller (Munich): Michael Best (patent attorney)
For Betapharm
Maiwald (Munich): Marco Stief, Heike Röder-Hitschke, Dirk Bühler, Renate Rieder (both patent attorneys)
In-house (Cambridge): Mujeebur Rahiman (head IP Europe Dr. Reddy’s)
Higher Regional Court Düsseldorf, 2nd Civil Chamber
Thomas Kühnen (presiding judge)
The complete Juve-Patent article can be downloaded under:
https://www.juve-patent.com/news-and-stories/cases/astrazeneca-appeal-rejected-in-generics-favourable-decision/
